- 期刊
- OpenAccess
Current Antithrombotic Therapy in Cardiac Disease
心臟病抗血栓藥物之最新治療
摘要
防止血栓及血栓是治療許多心臟病中最重要的一部份，它能降低此類血栓併發症之死亡率及罹患率。近年來研究均證實血小板凝集及血栓形成在冠狀動脈心臟病、心臟腔室疾病、瓣膜性心臟病、人工心臟瓣膜、以及冠狀動脈擴張術後再狹窄及阻塞均扮演著非常重要的角色。許多抗血栓藥物雖然很新、有效但迄今仍未完美，臨床上若使用時機適當、劑量正確、合適的適應症以及治療適切的時間均被證實有效。血栓栓塞高危險羣患者需要抗血栓藥物合併抗血小板凝集劑治療；中度危險羣患者需要抗血栓藥物治療；低危險羣患者只需抗血小板凝集劑治療。更新、更有效的抗血栓藥物現正發展試驗中，希望不久的未來，血栓栓塞併發症能大量地減少，甚至於完全防止。
並列摘要
The prevention of thromboisis and emboli is an important aspect in the therapy of many heart diseases and can greatly reduce the incidence of mortality and morbidity. Recent evidence strongly suggests the role of platelet aggregation and thrombosis in the progression of coronary artery disease, disease of the cardiac chambers, valvular heart disease, prosthetic heart valves, and restenosis and occlusion post coronary intervention. Many antithrombotic drugs, some quite new and potent but none still perfect, and presently in clinical use and have proven to be effective when used at the right time, in the correct dosage, for the indicated conditions and risks, and for the right duration. High risk conditions for thromboembolism warrant therapy with a combination of an anticoagulant with a platelet inhibitor; medium risk conditions necessitate treatment with anticoagulant alone, and low risk conditions may require only platelet inhibitors. Newer and more powerful antithrombotic drugs are now being developed and tested with the hope that thromboembolic complications can be greatly reduced or fully prevented in the near future.